1. Siegel R, Ma J, Zou Z, Jamal A. Cancer statistics 2014. CA Cancer J Clin. 2014;64(1):9–29.
  2. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J. 2008;31(3):492–501.
  3. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 2002;85(1):51–66.
  4. Von Roenn JH, Roth EL, Craig R. HIV-related cachexia: potential mechanisms and treatment. Oncology. 1992;49(2):50–4.
  5. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.
  6. Tsoli M, Robertson G. Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends Endocrinol Metab. 2013;24(4):174–83.
  7. Ferraro CD, Grant M, Koczywas M, Dorr-Uemura L. Management of anoreixacachexia in late stage lung cancer patients. J Hosp Palliat Nurs. 2012;14(6):1–12.
  8. Fox KM, Brooks JM, Gandra SR, Markus R, Chio CF. Estimation of cachexia among cancer patients based on four definitions. J Oncol. 2009;2009:693458.
  9. Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–9.
  10. Bozzetti F, Mariani L. Defining and classifying cancer cachexia: a proposal by the SCRINIO working group. J Parenter Enteral Nutr. 2009;33(4):361–7.
  11. van der Meij BS, Schoonbeek CP, Smit EF, Muscaritoli M, van Leeuwen PA, Langius JA. Pre-cacehxia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frame works. Br J Nutr. 2013;109(12):2231–9.
  12. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16:153–66.
  13. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systemic review of the epidemiological literature. Nutr J. 2010;9:69.
  14. Lin GN, Peng JW, Liu PP, Liu DY, Xiao JJ, Chen XQ. Elevated neutrophil-tolymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first line gefitinib or erlotinib treatment. Asia Pac J Clin Oncol. 2014. [EPUB ahead of print].
  15. Koch A, Fohlin H, Sorenson S. Prognostic significant of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first line palliative chemotherapy. J Thorac Oncol. 2009;4(3):326–32.
  16. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47.
  17. Ryan AS, Ivey FM, Prior S, Li G, Hafer-Macko C. Skeletal muscle hypertrophy and muscle myostatin reduction after resistive training in storke survivors. Stroke. 2011;42(2):416–20.
  18. Jafri SH, Shi R, Mills G. Advanced lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC):a retrospective review. BMC Cancer. 2013;13:158.
  19. Alberici Pastore C, Pavia Orlandi S, Gonzalez MC. Association between inflammatory-nutritional index and nutritional status in cancer patients. Nutr Hosp. 2013;28(1):188–93.
  20. Argilés JM, López-Soriano FJ, Toledo M, Betancourt A, Serpe R, Busquets S. The Cachexia Score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle. 2011;2(2):87–93.
  21. Douglas E, McMillan DC. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat Rev. 2014;40:685–91.
  22. Kasymjanova G, MacDonald N, Agulnik JS, et al. The predictive value of pretreatment inflammatory markers in advanced non-small cell lung cancer. Curr Oncol. 2010;17(4):52–8.
  23. Gagnon B, Agulnik JS, Gioulbasanis I, Kasymjanova G, Morris D, MacDonald N. Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers. Br J Cancer. 2013;109:2066–71.

Source: Clinical Medicine Insights: Oncology

Continue Reading